Sugi Predict

Sugi Predict / Compounds / SCHEMBL29599744

SCHEMBL29599744

SCHEMBL29599744

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](N)CC(=O)O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 14/20 0.66
▸ CCKBR P32239 1/20 0.66
▸ PTH1R Q03431 2/20 0.63
▸ RXFP1 Q9HBX9 1/20 0.61
▸ CRHR1 P34998 1/20 0.61
▸ CRHR2 Q13324 1/20 0.61
▸ KEAP1 Q14145 1/20 0.61
▸ GCGR P47871 1/20 0.60
▸ GIPR P48546 1/20 0.60
▸ IL23R Q5VWK5 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29599165 0.97 GLP1R (0.65) GLP1RCCKBRPTH1RRXFP1GCGR
Teduglutide SCHEMBL29358495 0.94 GLP1R (0.74) GLP1RCCKBRPTH1RCRHR1CRHR2
SCHEMBL29352277 0.93 GLP1R (0.75) GLP1RCCKBRPTH1RCRHR1CRHR2
SCHEMBL31182833 0.92 PTH1R (0.70) GLP1RCCKBRPTH1RRXFP1GCGR
SCHEMBL30658300 0.90 PTH1R (0.72) GLP1RCCKBRPTH1RRXFP1KEAP1
SCHEMBL29527049 0.89 PTH1R (0.72) GLP1RCCKBRPTH1RRXFP1KEAP1
SCHEMBL29546813 0.88 GLP1R (0.75) GLP1RCCKBR
SCHEMBL30607362 0.88 PTH1R (0.67) GLP1RCCKBRPTH1RRXFP1KEAP1
SCHEMBL31387893 0.88 GLP1R (0.65) GLP1RCCKBRPTH1RGCGRGIPR
SCHEMBL31387894 0.88 GLP1R (0.65) GLP1RCCKBRPTH1RGCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179130-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS ON TARGET THERAPEUTICS LLC 2025-06-05 — — US disclosed
US-20250051763-A1 METHODS AND SYSTEMS FOR CONDITIONALLY REGULATING GENE EXPRESSION FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) 2025-02-13 — — US disclosed
US-12060397-B2 Soluble lipidated ligand agents for treating eye inflammation TUFTS MEDICAL CENTER (US) 2024-08-13 — — US disclosed
US-20240084335-A1 CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-03-14 — — US disclosed
US-20240044871-A1 CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) 2024-02-08 — — US disclosed
CN-109312335-B Chimeric proteins and methods of modulating gene expression 斯坦福大学托管董事会 2023-10-24 — — CN disclosed
US-20230321146-A1 CHIMERIC POLYPEPTIDES AND METHODS OF USING THE SAME FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) 2023-10-12 — — US disclosed
US-11773411-B2 Chimeric proteins and methods of regulating gene expression THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-10-03 — — US disclosed
US-20220281989-A1 GPCR BINDING PROTEINS AND SYNTHESIS THEREOF Twist Bioscience Corporation 2022-09-08 — — US disclosed
US-11407837-B2 GPCR binding proteins and synthesis thereof Twist Bioscience Corporation (US) 2022-08-09 — — US disclosed
US-20220135633-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS ON TARGET THERAPEUTICS LLC 2022-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135633-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS LDLR, HDLBP, LIPG GLP1R 1209/4885CCKBR 2086/4885PTH1R 3702/4885
US-20250179130-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS LDLR, HDLBP, LIPG GLP1R 1209/4885CCKBR 2086/4885PTH1R 3702/4885
US-12060397-B2 Soluble lipidated ligand agents for treating eye inflammation LIPG, CD40, LDLR GLP1R 553/4885CCKBR 1573/4885PTH1R 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback